Pharmacokinetic Enhancement of Crizotinib plasma concentrations with Cobicistat or Itraconazole in Anaplastic Lymphoma Kinase positive advanced Non-Small Cell Lung Cancer Patients - PrECIsioN

Trial Profile

Pharmacokinetic Enhancement of Crizotinib plasma concentrations with Cobicistat or Itraconazole in Anaplastic Lymphoma Kinase positive advanced Non-Small Cell Lung Cancer Patients - PrECIsioN

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Crizotinib (Primary) ; Cobicistat; Itraconazole
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Acronyms PrECIsioN
  • Most Recent Events

    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top